EMA: Granting of a marketing authorisation for the medicinal product Siltuximab [Sylvant] for the treatment of multicentric Castleman’s Disease (MCD) recommended.

Last Updated on

On 20 March 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Sylvant, 100 mg and 400 mg, Powder for concentrate for solution for infusion intended for the treatment of multicentric Castleman’s disease (MCD). Sylvant was designated as an orphan medicinal product on 30 November 2007. The applicant for this medicinal product is Janssen-Cilag International NV. They may request a re-examination of any CHMP opinion, provided they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

The active substance of Sylvant is siltuximab, a human‑mouse chimeric monoclonal antibody that specifically binds to and neutralizes human IL-6 with high affinity. The benefits with Sylvant are its ability to reduce the tumour burden and to improve the symptoms in MCD patients. The most common side effects are infections (including upper respiratory tract infections), pruritus, and maculopapular rash. A pharmacovigilance plan for Sylvant will be implemented as part of the marketing authorisation.

The approved indication is: “Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus‑8 (HHV‑8) negative”. It is proposed that Sylvant should be administered by qualified healthcare professionals and under appropriate medical supervision.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CHMP, on the basis of quality, safety and efficacy data submitted, considers there to be a favourable benefit-to-risk balance for Sylvant and therefore recommends the granting of the marketing authorisation.

Tags: , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • MicroRNA exhibit unexpected function in driving cancer February 20, 2020
    Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer. New research from Thomas Jefferson University has revealed that both strands of some microRNA coordinate to act on […]
  • New therapy stops seizures in mouse model of rare childhood epilepsy February 20, 2020
    Seizure disorders in babies are frightening and heartbreaking. A new basic science breakthrough offers hope for a potential treatment for rare developmental and epileptic encephalopathies resulting from a single genetic mutation. The gene in question, called SCN8A, controls a sodium channel that allows neurons to transmit an electric signal. When this gene is mutated, these […]
  • Scientists find many gene 'drivers' of cancer, but warn: Don't ignore 'passengers' February 20, 2020
    A massive analysis of the entire genomes of 2,658 people with 38 different types of cancer has identified mutations in 179 genes and gene regulators as "drivers"—variations in DNA sequences that lead to the development of cancer.
  • A deep dive into cellular aging February 20, 2020
    Scientists at Sanford Burnham Prebys Medical Discovery Institute and Harvard University have discovered that mitochondria trigger senescence, the sleep-like state of aged cells, through communication with the cell's nucleus—and identified an FDA-approved drug that helped suppress the damaging effects of the condition in cells and mice. The discovery, published in Genes & Development, could lead […]
  • New model of C. elegans helps progress study of rare genetic disease February 20, 2020
    The IDIBELL Neurometabolic Diseases group, with international collaboration, has identified a model of chromosome X-linked adrenoleukodystrophy (X-ALD) in C. elegans. X-ALD is a rare disorder of the nervous system with no available treatment.
  • New findings: Pacific marine national monuments do not harm fishing industry February 20, 2020
    The University of Hawaii at Manoa research team analyzed observer records of individual fishing events, logbook summary reports and detailed satellite data on vessel movements.
  • Research team tackles superbug infections with novel therapy February 20, 2020
    Superbug infections kill 35,000 people in the US annually. A team of researchers has found that a treatment known as AB569 kills pseudomonas aeruginosa in humanized cells in mouse models. The treatment does not harm these humanized cells.
  • Risk of coronavirus importation in Africa February 20, 2020
    Egypt, Algeria and Republic of South Africa are the African countries most at risk for coronavirus COVID-19 importation in the continent, due to high air traffic with the contaminated Chinese provinces. But these countries are also among the best equipped on the continent to quickly detect and deal with new cases. In other African countries, […]
  • Researchers say extended antidepressant use creates physical dependence February 20, 2020
    Researchers explain symptoms associated with Antidepressant Discontinuation Syndrome and provide a schedule for tapering various classes of antidepressants. Patients who stop medication without tapering often experience flulike symptoms, insomnia, nausea, imbalance, sensory disturbances often described as electric shocks or 'brain zaps', and hyperarousal.
  • Old carbon reservoirs unlikely to cause massive greenhouse gas release February 20, 2020
    As global temperatures rise, permafrost and methane hydrates -- large reservoirs of ancient carbon -- have the potential to break down, releasing enormous quantities of the potent greenhouse gas methane. But would this methane actually reach the atmosphere? University of Rochester researchers and their collaborators found that even if methane is released from these natural […]
Top